Key result
PCSK9 antibodies may improve plaque stability and reduce inflammation and thrombosis in acute coronary syndrome.
Answers are grounded in this paper and cite their sources.
Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) are an emerging therapy for dyslipidemia. Acute coronary events induce a dynamic increase of PCSK9 levels that may play a role in plaque vulnerability of both culprit and nonculprit coronary vessels. Growing evidence highlights a potential key role of PCSK9 antibodies in managing acute coronary syndrome. This review describes the influence of PCSK9 antibodies on plaque composition and instability, as well as the pharmacokinetic profile and the potential anti-inflammatory and antithrombotic mechanisms associated with PCSK9 inhibition that may confer benefits during the early phase of acute coronary syndrome. The authors posit a rationale for the use of PCSK9 antibodies in patients with acute coronary syndrome and highlight the need for further investigation in this area.
No takes yet. Share an insight, caveat, or question.
Navarese et al. (2016) conducted a review in Acute coronary syndrome and dyslipidemia. Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies was evaluated. PCSK9 monoclonal antibodies may reduce plaque instability and provide anti-inflammatory and antithrombotic benefits in acute coronary syndrome, though no quantitative results are reported.
Synapse has enriched 10 related papers. Consider them for comparative context: